Hyperoxaluria Clinical Trial
Official title:
Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk
The purpose of this study is to ascertain whether certain supplements promote excessive urinary oxalate excretion and increase the risk for calcium oxalate kidney stones. Supplements that enhance urinary oxalate excretion, as a result of their oxalate concentration or from some other mechanism (e.g., providing substrate for oxalate biosynthesis) will be identified by the investigators.
Status | Completed |
Enrollment | 45 |
Est. completion date | October 2016 |
Est. primary completion date | October 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - At least 18 years of age, no prior personal history of kidney stones Exclusion Criteria: - Personal history of kidney stones (by subjects' report); known allergy to any of the dietary supplements to be used in the study (by subjects' report); short bowel; active ulcerative colitis or irritable bowel disease; Crohns or Celiac disease; renal tubular acidosis; current use of topiramate or other carbonic anhydrase inhibitor, steroids, allopurinol, thiazide diuretics, or supplemental ascorbic acid >250 mg/day. |
Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
United States | Department of Urology, School of Medicine & Public Health, University of Wisconsin | Madison | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Within-subject change in 24-hour urinary oxalate excretion from before and after supplementation | 24-hour urine samples will be analyzed for oxalate by ion chromatography. The difference in oxalate between the baseline (non-supplement) and supplement phase will be assessed. | 7 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06138327 -
A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
|
Phase 1 | |
Completed |
NCT02547805 -
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days
|
Phase 2 | |
Completed |
NCT02289755 -
Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
|
Phase 2 | |
Completed |
NCT02038543 -
Hydroxyproline Influence on Oxalate Metabolism
|
Phase 1/Phase 2 | |
Completed |
NCT03095885 -
A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria
|
N/A | |
Recruiting |
NCT02780297 -
Prospective Research Rare Kidney Stones (ProRKS)
|
||
Completed |
NCT01127087 -
Oxazyme in Patients With Hyperoxaluria
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05443932 -
Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients
|
Phase 4 | |
Completed |
NCT04756024 -
Reference Interval of Spot Urinary Oxalate to Creatinine Ratio in Children
|
||
Completed |
NCT02503345 -
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones
|
Phase 2 | |
Completed |
NCT00199459 -
Proteomic Study of Urinary Stone Disease
|
N/A | |
Completed |
NCT04119765 -
Plasma Oxalate in Patient With Short Bowel
|
||
Completed |
NCT00283387 -
Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria
|
Phase 2 | |
Completed |
NCT00587041 -
Use of Oral Probiotics to Reduce Urinary Oxalate Excretion
|
Phase 1/Phase 2 | |
Completed |
NCT04571359 -
Spot Urine Oxalate to Creatinine Ratio and 24 Hours Urinary Oxalate
|
||
Withdrawn |
NCT00280215 -
Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria
|
Phase 3 | |
Completed |
NCT00588120 -
Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria
|
Phase 1 |